Resources from the same session
258MO - Niraparib plus abiraterone acetate plus prednisone (NIRA+AAP) as first-line treatment in patients with BRCA+ metastatic castration-resistant prostate cancer (mCRPC): Second interim analysis in the Asian subgroup of the MAGNITUDE study
Presenter: Marniza Saad
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
260MO - Impact of starting treatment choice in metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: masaki Shiota
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 258MO and 260MO
Presenter: Jan Oldenburg
Session: Mini oral session: Genitourinary tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Mini oral session: Genitourinary tumours
Resources:
Webcast
261MO - Effect of liver and metabolic toxicity on survival and quality of life in patients with high-volume, metastatic hormone-sensitive prostate cancer receiving rezvilutamide in the CHART trial
Presenter: Hong Luo
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
262MO - Prognostic significance of deep and rapid prostate-specific antigen (PSA) response with docetaxel (DOC) or abiraterone (ABI): A territory-wide real-world analysis of 574 Asian metastatic hormone-sensitive prostate cancer (mHSPC) patients
Presenter: Darren Poon
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
263MO - Enzalutamide versus abiraterone plus prednisolone for Japanese non-metastatic castration-resistant prostate cancer patients: Sub-analysis from ENABLE for PCa, a multicenter, randomized controlled trial
Presenter: Kouji Izumi
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
210MO - Low dose nivolumab with TKI in mRCC: Dosing strategies, de-escalation and survival among self-paying patients in India
Presenter: Ajoy John
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
211MO - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Presenter: Eiji Kikuchi
Session: Mini oral session: Genitourinary tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 210MO and 211MO
Presenter: Yuji Miura
Session: Mini oral session: Genitourinary tumours
Resources:
Slides
Webcast